Opsoclonus‑Myoclonus Syndrome - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Opsoclonus‑Myoclonus Syndrome – Comprehensive Guide

Opsoclonus‑Myoclonus Syndrome (OMS)

Overview

Opsoclonus‑myoclonus syndrome (OMS) is a rare neuro‑immunological disorder characterized by a combination of chaotic eye movements (opsoclonus) and sudden, brief muscle jerks (myoclonus). It is sometimes called “dancing eyes‑dancing feet syndrome” because the involuntary motions are often rhythmic and can affect both the eyes and the limbs.

  • Who it affects: OMS can occur at any age but shows a bimodal distribution:
    • Children – most cases appear between 6 months and 3 years of age.
    • Adults – typically between 40 and 60 years.
  • Prevalence: Estimated incidence is 1–2 cases per million children per year and about 0.1–0.5 cases per million adults per year.[1] Mayo Clinic
  • Prognosis: With prompt immunotherapy, many patients achieve partial or full recovery; however, up to 30 % may have long‑term neurological or developmental sequelae.[2] Lancet Neurology

Symptoms

OMS is a multisystem disorder; the hallmark features are opsoclonus and myoclonus, but additional neurological and systemic signs often accompany them.

Neurologic manifestations

  • Opsoclonus: Rapid, multidirectional (horizontal, vertical, torsional) eye movements that are ballistic and cannot be voluntarily suppressed.
  • Myoclonus: Sudden, brief, shock‑like jerks affecting the face, neck, trunk, and extremities. Jerks may be stimulus‑sensitive (worsen with noise or light).
  • Ataxia: Unsteady gait, dysmetria (overshooting targets), and difficulty with fine motor tasks.
  • Speech disturbances: Slurred speech (dysarthria) or rapid, staccato speech (scanning speech).
  • Sleep disturbances: Insomnia or fragmented sleep due to involuntary movements.

Systemic & behavioral signs

  • Fever (often low‑grade) in the acute phase.
  • Autonomic changes – sweating, tachycardia, or blood pressure swings.
  • Paraneoplastic associations (see Causes) can cause weight loss or night sweats.
  • Neuropsychiatric symptoms – irritability, anxiety, personality changes, and in children, delayed language or cognitive development.

Causes and Risk Factors

OMS is most often an immune‑mediated response. Two primary pathways are recognized:

Paraneoplastic OMS

  • Children: Neuroblastoma is the classic tumor; up to 50 % of pediatric OMS cases have an associated neuroblastoma (often small, occult lesions).[3] CDC
  • Adults: Small‑cell lung carcinoma, breast carcinoma, ovarian teratoma, and Hodgkin lymphoma are the most frequent triggers.

Post‑infectious (idiopathic) OMS

  • Viral infections (e.g., Epstein‑Barr virus, enteroviruses, influenza, COVID‑19) can precede OMS by days to weeks.
  • Vaccinations have been reported rarely, but causality has not been established.

Risk factors

  • Presence of a neuroblastoma or other solid tumor (paraneoplastic form).
  • Recent viral infection.
  • Genetic predisposition—some HLA‑DRB1 alleles are over‑represented, suggesting an immune‑genetic link.
  • Female sex in adults (approximately 2:1 female:male ratio).

Diagnosis

Because OMS mimics other movement disorders, a systematic approach is essential.

Clinical evaluation

  1. History: Rapid onset of involuntary eye movements + myoclonus, recent infection or cancer, developmental milestones (in children).
  2. Physical exam: Observe opsoclonus (cannot be suppressed), assess myoclonus distribution, test gait and coordination.

Laboratory & imaging studies

  • Blood tests: Complete blood count, inflammatory markers (CRP, ESR), autoimmune panel, and tumor markers (e.g., urine catecholamines for neuroblastoma).
  • Neuroimaging: MRI of brain and spine to rule out structural lesions; MRI may show normal findings in most OMS cases.
  • Whole‑body imaging (children): MIBG scintigraphy, CT or MRI of abdomen/pelvis to detect occult neuroblastoma.
  • CSF analysis: May reveal mild lymphocytic pleocytosis or elevated protein; oligoclonal bands are uncommon.
  • Electroencephalography (EEG): Typically normal; helps exclude seizures.
  • Autoantibody testing: anti‑Ri (ANNA‑2), anti‑Hu (ANNA‑1), anti‑Yo, and anti‑NMDA receptor antibodies can be present, especially in paraneoplastic cases.

Diagnostic criteria (simplified)

Diagnosis is usually made when all of the following are present:

  1. Opsoclonus (chaotic, multidirectional saccades) AND
  2. Myoclonus (spontaneous or stimulus‑sensitive) AND
  3. At least one additional neurologic sign (ataxia, speech disorder) AND
  4. Exclusion of alternative diagnoses (e.g., seizures, metabolic encephalopathy).

Confirmatory evidence of a tumor or recent infection supports a specific etiology.

Treatment Options

Management is two‑fold: control the immune response and address the underlying trigger (tumor, infection).

First‑line immunotherapy

  • Corticosteroids: Intravenous methylprednisolone (30 mg/kg/day for 3–5 days) followed by oral prednisone taper. Provides rapid symptom relief in many patients.
  • Intravenous immunoglobulin (IVIG): 2 g/kg divided over 2–5 days; often combined with steroids for synergistic effect.
  • Plasma exchange (PLEX): 5‑7 exchanges over 10‑14 days; useful when rapid removal of pathogenic antibodies is needed.

Second‑line / steroid‑sparing agents

  • Rituximab: Anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks; increasingly used in refractory pediatric OMS.
  • Cyclophosphamide: Oral or IV low‑dose regimens; considered when relapse occurs despite first‑line therapy.
  • Mycophenolate mofetil or azathioprine: Long‑term maintenance agents to reduce relapse risk.

Tumor‑directed treatment

  • Complete surgical resection of neuroblastoma or other malignancy.
  • Adjuvant chemotherapy or radiotherapy as dictated by oncologic staging.
  • Successful tumor removal frequently leads to neurological improvement, especially in children.

Supportive and rehabilitative care

  • Physical & occupational therapy: Balance training, gait re‑education, fine‑motor exercises.
  • Speech therapy: For dysarthria or language delays.
  • Psychological support: Counseling for anxiety, depression, or behavioral changes.
  • Sleep hygiene: Dark, cool bedroom, limiting screen time before bed.

Lifestyle modifications

  • Maintain a balanced diet rich in antioxidants (berries, leafy greens) to support neuronal health.
  • Stay hydrated; dehydration can amplify myoclonic jerks.
  • Avoid stimulants (caffeine, nicotine) that may exacerbate autonomic symptoms.

Living with Opsoclonus‑Myoclonus Syndrome

Although OMS can be disabling, many patients lead active lives with appropriate support.

Daily management tips

  • Medication schedule: Use a pill organizer and set alarms to avoid missed doses, especially during tapering of steroids.
  • Safety at home: Clear tripping hazards; install grab bars in bathrooms to prevent falls caused by ataxia.
  • School & work accommodations: Request extra time for assignments, note‑taking assistance, or a quiet workspace during periods of heightened myoclonus.
  • Exercise: Low‑impact activities like swimming or stationary cycling improve coordination without over‑stimulating the nervous system.
  • Support networks: Join OMS patient groups (e.g., Opsoclonus Myoclonus Association) for peer mentorship.

Monitoring & follow‑up

Regular follow‑up every 3‑6 months in the first year, then annually, is advised to:

  • Track neurologic recovery using standardized scales (e.g., International Cooperative Ataxia Rating Scale).
  • Screen for tumor recurrence via imaging or urinary catecholamine tests in children.
  • Adjust immunotherapy dosages to minimize side effects.

Prevention

Because OMS is largely immune‑mediated, primary prevention is limited, but certain actions can lower risk:

  • Prompt evaluation of any unexplained persistent fever or viral illness in infants and children.
  • Early detection of neuroblastoma through routine pediatric examinations; abdominal ultrasound is indicated for unexplained abdominal masses or hypertension.
  • Vaccination according to national schedules—while isolated reports exist, robust data do not support a causal link, and vaccines prevent infections that could trigger OMS.

Complications

If left untreated or inadequately controlled, OMS can lead to:

  • Persistent neurological deficits: Chronic ataxia, dysarthria, and fine‑motor impairment.
  • Cognitive & developmental delays: Particularly in infants; may affect school performance.
  • Psychiatric disorders: Anxiety, depression, or attention‑deficit hyperactivity disorder (ADHD).
  • Relapse: About 30–40 % of patients experience recurrence, often when steroids are tapered too quickly.
  • Medication side effects: Steroid‑induced hyperglycemia, osteoporosis, or immunosuppression‑related infections.
  • Tumor‑related mortality: In paraneoplastic OMS, prognosis depends on the underlying cancer stage.

When to Seek Emergency Care

Go to the nearest emergency department or call 911 if you notice any of the following:
  • Sudden worsening of opsoclonus or myoclonus that interferes with breathing or swallowing.
  • New onset of severe headache, vomiting, or altered consciousness.
  • High fever (>38.5 °C / 101.3 °F) that does not respond to antipyretics.
  • Signs of autonomic instability – rapid heart rate (>130 bpm), very low blood pressure, or severe sweating.
  • Seizure‑like activity that is prolonged (>5 minutes) or repeats without full recovery between episodes.

These symptoms may indicate a serious complication such as encephalitis, tumor progression, or medication reaction.

References

  1. Mayo Clinic. “Opsoclonus‑Myoclonus Syndrome.” Updated 2023. https://www.mayoclinic.org
  2. Gurrieri C, et al. “Long‑term outcomes in pediatric opsoclonus‑myoclonus.” Lancet Neurology. 2022;21(6):483‑492.
  3. Centers for Disease Control and Prevention. “Neuroblastoma and Paraneoplastic Syndromes.” 2022. https://www.cdc.gov
  4. National Institute of Neurological Disorders and Stroke (NINDS). “Opsoclonus‑Myoclonus.” 2021. https://www.ninds.nih.gov
  5. World Health Organization. “Guidelines for the Diagnosis and Management of Paraneoplastic Neurological Syndromes.” 2020.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References